Ecurater Journals
ISSN: 2833-7859

Archives of Cancer Research & Medicine

Aim & Scope

The Scope of this Journal includes Cancer Research, Cancer Medicine, Cancer Surgery, Tumor, Oncology, Immune-Oncology, Carcinogenesis, Melanoma, Sarcoma, Metastasis, Chemotherapy, Leukemia, Cancer Therapeutics, Cancer Epidemiology, Cancer Prevention, Clinical Trials, Cancer Cytopathology, Stem Cell Therapy, DNA Repair in Cancer Therapy and related areas.

Editorial Board

Dr. Adrián P. Huñis
Medical Specialist in Clinical Oncology
Buenos Aires, Argentina
Dr. Michael J. Gonzalez
Professor
University of Puerto Rico Medical Sciences
Puerto Rico, U.S.A
Dr. Alain L. Fymat
President, CEO and Institute Professor
International Institute of Medicine and Science
Rancho Mirage, California, U.S.A
Dr. Jonas Cicenas
Senior Scientist
Institute of Biochemistry, Vilnius University Life Sciences Center
Vilnius, Lithuania, Europe
Dr. Sanjay Singh Chandel
Associate Professor
Department of Radiation Oncology, G.R Medical College
Gwalior, M.P., India
Dr. Bhuvnesh K. Sharma
Senior Director, R&D (Translational Oncology)
ScyTeK Laboratories Inc.
Logan, UT, USA
Dr. Daniela Capdepon
Oncologist Consultant & Senior Medical Director
Campana Cancer Centre
Argentina
Dr. Daniel Gandia
Medical Director, Hematology and Oncology
University of Buenos Aires
Buenos Aires, Argentina
Dr. Bhanu Patibandla
Director, Lung Nodule & Thoracic Oncology Program
PeaceHealth Southwest Medical Center
Vancouver, Washington, United States
Nupur K Das
Research Investigator
University of Michigan
United States
Shivanand Pudakalakatti
Research Investigator
University of Texas MD Anderson Cancer Center
United States

Article in Press

Special Issue

Cancer Treatment – From Immunotherapy To Gene Therapy And Beyond

Article Type : Editorial
Author : Alain L. Fymat *

Abstract

Cancer is the oldest disease having affected humankind. Attempts to treat it have taken the shape of a “war” and have best been described in military terms. So far, despite winning some battles, we have waged that war without focus and unsuccessfully for the past 4,000 years with an accelerated campaign only during the last four decades. We rarely saw the enemy as it hid behind other diseases (cholera, dropsy, leprosy, plague, pneumonia, smallpox, and tuberculosis) and mostly affected the older populations. However, with increasing lifespan and a partial clearing of these other diseases, cancer came back in full force and roaring. From the earliest accounts dating to the Greek historian Herodotus (440 BC) within the context of breast cancer, the latest pronouncements of the World Health Organization (WHO) are that “ … cancer is the second leading cause of death globally, accounting for an estimated 9.6 million deaths, or one in six deaths in 2018”. For 2020, the numbers of estimated cases/deaths for the various types of organ cancers were: breast (2.26 million/685,000), colon and rectum (1.93 million/935,000), liver (830,000 deaths), lung (2.21 million/1.8 million), prostate (1.41 million), skin (non-melanoma) (1.20 million), and stomach (1.09 million/769,000). Further, for 2021, model-based projections by the American Cancer Society (ACS) predicted 1,898,160 new cases and 608,570 additional deaths in the U.S.

Abstract Download Article View Full Article

Current Issue

Expected Usefulness of Fourth Dose of COVID-19 for Cases with Underlying B cell Malignancy

Article Type : Research
Author : Rujittika Mungmunpuntipantip*, Viroj Wiwanitkit
Abstract Download Article View Full Article

Renal Metastasis in Carcinoma Pyriform Fossa treated with SBRT: A Case Report and a Brief Review

Article Type : Case Report
Author : Murali Paramanandhan*, Anil Kumar MR, Sandeep Naik, Suresh Babu, Shanthi Veluswamy and Gayana S
Abstract Download Article View Full Article

Magnetic Resonance Techniques for Assessing in Vivo pH

Article Type : Review
Author : Shivanand Pudakalakatti*, Renee Chin, Mark D Pagel and Pratip K Bhattacharya
Abstract Download Article View Full Article

Archives

volume 1

Issue1

Cancer Treatment – From Immunotherapy To Gene Therapy And Beyond

Article Type : Editorial
Author : Alain L. Fymat *

Abstract

Cancer is the oldest disease having affected humankind. Attempts to treat it have taken the shape of a “war” and have best been described in military terms. So far, despite winning some battles, we have waged that war without focus and unsuccessfully for the past 4,000 years with an accelerated campaign only during the last four decades. We rarely saw the enemy as it hid behind other diseases (cholera, dropsy, leprosy, plague, pneumonia, smallpox, and tuberculosis) and mostly affected the older populations. However, with increasing lifespan and a partial clearing of these other diseases, cancer came back in full force and roaring. From the earliest accounts dating to the Greek historian Herodotus (440 BC) within the context of breast cancer, the latest pronouncements of the World Health Organization (WHO) are that “ … cancer is the second leading cause of death globally, accounting for an estimated 9.6 million deaths, or one in six deaths in 2018”. For 2020, the numbers of estimated cases/deaths for the various types of organ cancers were: breast (2.26 million/685,000), colon and rectum (1.93 million/935,000), liver (830,000 deaths), lung (2.21 million/1.8 million), prostate (1.41 million), skin (non-melanoma) (1.20 million), and stomach (1.09 million/769,000). Further, for 2021, model-based projections by the American Cancer Society (ACS) predicted 1,898,160 new cases and 608,570 additional deaths in the U.S.

Abstract Download Article View Full Article

Community-Based Psychosocial Support Centers for Cancer Patients and Their Relatives: Use, Evaluation and Effect

Article Type : Research
Author : Adriaan Visser

Abstract

Aim

Community-Based Psychosocial Support Centers for cancer patients and their relatives (CBPSCs) offer easily accessible contacts with fellow patients and support by trained volunteers in the Netherlands. We studied the characteristics of visitors of CBPSCs, which social support and/or therapy they receive, if these services meet their needs, how satisfied they are with the help, and if it does affect their Health Quality of Life (HQoL).

Methods

The role of 20 CBPSCs was explored in semi-structured interviews among 34 visitors. Regarding their contacts with CBPSCs (Study 1), additionally, in 25 CBPSCs, 701 visitors s filled out a web-based questionnaire about their experiences with CBPSCs (Study 2). Within this second study, 203 participants filled out a questionnaire again after 3-5 months (Study 3).

Results

The studies confirm the significance of CBSCs contacts, resulting in increased communication about their illness, talks with fellow patients about their problems. Most visitors are not referred to CBPSCs by health care professionals, but visit on their own initiative and contacts. Patients often visit CBPSCs once a week or monthly. The visitors are mainly highly educated women with breast cancer over 60 years of age. The social support involves especially creative and leisure time activities. The therapies are individual therapy sessions, groups on creative therapy, mindfulness, body-orientation, and bereavement. Evaluation of activities and therapies is positive, varying from 7.2 to 8.6 on a 10-point scale. Study 3 shows that after a few months the HQoL decreased significantly for all other visitors, but did not change for serious ill patients.

Discussion and Conclusion

CBPSCs play an important and highly evaluated role in psycho-oncology. Insight in effects of visits is still limited. Differences in the health care organization restrict the comparability with the CBPSCs in other countries. More studies are needed to show the effects of CBPSCs.

Abstract Download Article View Full Article

Pattern of Neuroblastoma Among Children in Basra Pediatric Oncology Center

Article Type : Research
Author : Marwa Sabah Abdul Rahman, Janan G. Hasan*, Athar Abdul Samad and Hussam M.Salih

Abstract

Background Neuroblastoma is a neoplasm of the sympathetic nervous system, is the second most common extracranial malignant tumor of childhood, it accounting for8% to 10% of all childhood cancers and for approximately15% of cancer deaths in children.

Objective To designated demographic and clinical geographies of neuroblastoma in Basra pediatric oncology center.

Patients and Methods A retrospective study was carried out from October 2016 till end of April 2017to assessed characteristics features of patients with neuroblastoma who have been registered and admitted to the Basrah Hospital of Pediatric Oncology center during the period from the I st of January 2004 till the end of December 2016.

Results The total cases of neuroblastoma admitted to the Center during that period were 179. Their age ranges from one month up to 14 years, 104 male and 75 female. A special data sheet was designed for the purpose of the study; the information was taken from patient’s files; name, age (date of birth), date of admission, gender and residence. The study showed that the percentage of patients with neuroblastoma treated in Basrah Pediatric Oncology Center have increased gradually from 5% at 2004 to 13.4% at 2015.

The highest frequency of neuroblastoma was found in the age group (1-5 years) that included 117 patients 65.4%.
Higher numbers of patients with neuroblastoma were from the center and northern areas of Basrah (22.3%, 12.3%) respectively and to a lesser extent in western (9%) and, southern (9%), and eastern (2.2%). Other governorates like ThiQar and Maysan account for high rates (28.5% and 21.8% respectively) of admissions in Basrah Paediatric Oncology Center.

This study revealed that most patients with neuroblastoma commonly presented with abdominal mass,gastrointestinal track symptoms and other symptom like pallor and fever, and most patients presented in stage IV (51.39%) or stage III (39.66%) of the disease. Distant metastasis occurs in 93(51.9%), the most common site of metastasis was bone marrow 72 (40.2).

The overall mortality was 92(51.4%), The outcome of patients with neuroblastoma also varied with age, the age group < one year have low percentage of death (7.8%) than the age group 1-5 year(38.0%), the mortality rate was high in last 5 years 2012-2016 (22.3%) while the years from 2008-2011, 2004-2007 percentage of mortality low (16.8%, 12.3%) respectively, the non-compliance was decrease in the last 5 year 2012-2016( 6.7%), high percentage of non-compliance in the period from 2008-2011 (7.8%).

Conclusion None compliance or discontinuation of treatment is an important dilemma for a disease, so increase awareness about early sign and symptoms of the disease and improving the diagnostic facilities, with psychological support in order to resolve this problem.

Abstract Download Article View Full Article

Upcoming Special Issues